



Tuberculosis Country Profile 2021 Pakistan

Source: Global tuberculosis report 2021. Geneva: World Health Organization

Disclaimer: Tuberculosis country profiles are generated automatically based on data reported by countries and which are held in WHO's global TB database.

Tuberculosis profile: Pakistan

Population 2020: 221 million

Estimates of TB burden*, 2020

	Number	(Rate per 100 000 population)
Total TB incidence	573 000 (409 000-764 000)	259 (185-346)
HIV-positive TB incidence	14 000 (9 100-19 000)	6.2 (4.1-8.7)
HIV-negative TB mortality	44 000 (36 000-53 000)	20 (16-24)
HIV-positive TB mortality	2 000 (1 700-2 500)	0.92 (0.75-1.1)

Universal health coverage and social protection*

TB treatment coverage (notified/estimated incidence), 2020	48% (36-67)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2020	8% (6-11)

TB case notifications, 2020

Total new and relapse	272 990
- % tested with rapid diagnostics at time of diagnosis	46%
- % with known HIV status	29%
- % pulmonary	81%
- % bacteriologically confirmed [^]	49%
- % children aged 0-14 years	14%
- % women (aged ≥15 years)	41%
- % men (aged ≥15 years)	45%
Total cases notified	276 736

TB/HIV care in new and relapse TB patients, 2020

	Number	(%)
Patients with known HIV status who are HIV-positive	556	0.7%
- on antiretroviral therapy	364	65%

Drug-resistant TB care**, 2020

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases [^]	71%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases [^]	76%
Laboratory-confirmed cases - MDR/RR-TB ^{^^}	2 689
Patients started on treatment - MDR/RR-TB ^{^^^}	2 372
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^{^^}	831
Patients started on treatment - pre-XDR-TB or XDR-TB ^{^^^}	669
MDR/RR-TB cases tested for resistance to any fluoroquinolone	1 918

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2019	93%	326 455
Previously treated cases, excluding relapse, registered in 2019	85%	6 341
HIV-positive TB cases registered in 2019	81%	686
MDR/RR-TB cases started on second-line treatment in 2018	70%	3 076
XDR-TB cases started on second-line treatment in 2018	49%	75

TB preventive treatment, 2020


% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5 years) household contacts of bacteriologically-confirmed TB cases on preventive treatment	5% (4.5-5.4)

TB financing

National TB budget, 2021 (US\$ millions)	153
- Funding source, domestic	2.4%
- Funding source, international	40%
- unfunded	58%


Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)




HIV-negative TB mortality

(Rate per 100 000 population per year)




Incidence, Notified cases by age group and sex, 2020

(Number)




Cases attributable to five risk factors, 2020

(Number)



Total budget

(US\$ millions)



* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.

** RR is TB resistant to rifampicin (R); MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone

[^] Calculated for pulmonary cases only

^{^^} Includes cases with unknown previous TB treatment history

^{^^^} Includes patients diagnosed before 2020 and patients who were not laboratory-confirmed